ALC is already in commercial stage and not a biotech start-up and they spends way too much capital to make those revenue, big red flag. There is another biotech start-up which has massive revenue potential due to their technology, very high MC for a biotech start-up but if you look at this technology's market for multiple products you can see why it's high despite not yet in commercial stage and they have cash balance of $100M.
RAP Price at posting:
20.5¢ Sentiment: None Disclosure: Not Held
